Merck: Keytruda in Combination Reduced Risk of Death in Certain Esophageal Cancer Patients
September 21 2020 - 1:38PM
Dow Jones News
By Stephen Nakrosis
Merck & Co. Inc. on Monday said data from a Phase 3 trial of
Keytruda in combination with platinum-based chemotherapy showed the
treatment led to a reduced risk of death in certain esophageal
cancer patients.
The company said its KEYNOTE-590 trial was evaluating Keytruda
in combination with platinum-based chemotherapy as a "first-line
treatment of patients with locally advanced or metastatic
esophageal and gastroesophageal junction cancer."
According to Merck, "Keytruda plus chemotherapy demonstrated
superior overall survival and progression-free survival versus
chemotherapy in these patients regardless of PD-l1 expression
status and tumor histology." Merck also said, "Keytruda in
combination with chemotherapy significantly improved overall
survival, reducing the risk of death by 27% versus chemotherapy in
all randomized patients."
The data were presented at the European Society for Medical
Oncology Virtual Congress 2020 on Sept. 21, Merck said.
Merck added that it will be sharing the data with regulatory
authorities worldwide.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 21, 2020 13:23 ET (17:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024